about
LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: implication for mitochondrial dysfunction in Parkinson's diseaseRotenone, deguelin, their metabolites, and the rat model of Parkinson's diseaseChronic systemic pesticide exposure reproduces features of Parkinson's diseaseAutomated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro.Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents.Neurotoxic in vivo models of Parkinson's disease recent advances.Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's diseaseGlutamatergic influences on the basal ganglia.Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease.Animal models of Parkinson's disease.Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease.Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line.Toxin models of mitochondrial dysfunction in Parkinson's disease.Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.Mitochondrial iron metabolism and its role in neurodegeneration.3-Nitropropionic acid exacerbates N-methyl-D-aspartate toxicity in striatal culture by multiple mechanisms.Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism.Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells.Paraquat neurotoxicity is distinct from that of MPTP and rotenone.Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals.Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation.Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease.DJ-1 expression modulates astrocyte-mediated protection against neuronal oxidative stress.Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment.Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion.Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions.Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.Mouse ES cells overexpressing DNMT1 produce abnormal neurons with upregulated NMDA/NR1 subunit.Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.Biomedicine. Parkinson's--divergent causes, convergent mechanisms.Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
P50
Q23923990-40D59C34-51C7-4CC9-83B2-38AA7CEE10A3Q28292922-59A123C7-99C3-4CCD-A44C-56DE1C71C8A7Q29614763-0203CDF7-A9E5-44A1-B137-D0F9510F678FQ30537879-01F9FE6F-94DC-46A4-95F3-7F601ED9BC1EQ30573637-04793026-9766-40EC-9E87-4A3E7920B0B3Q33544048-BCA3B737-585C-43FD-A624-4D19F456B5C2Q33708283-9DB220E5-7E4D-4893-9067-09CD3FDEBB5DQ33899839-D11CEFBD-F04C-42F5-B89D-FB14E0E24ACBQ34090228-028B9351-B19D-47F3-A3A3-36D2722F9645Q34221541-D65229E1-F81A-462F-B6A4-529032BCF19FQ34556515-D29F1EDB-6C68-4C86-8E78-A76C077C9550Q34596189-BA9788DD-D43A-4F29-BFE8-C5CE5CE8FD2CQ34806527-92BBE182-EA99-41BA-9326-5D522AF11E7DQ35058875-C1476527-A712-434B-B320-07C7563ABB5BQ35133165-F426ACFA-86BC-4C0F-990D-48D37DBE79D9Q35799141-E78E43A9-A7E9-493E-983D-581748F92D36Q36553302-DC0B304B-2B87-490D-A2F0-CCBE0450BA87Q37424610-F1076CE5-5160-46FD-9F12-11E3739E4D55Q37621247-C5A86C8F-DE24-4B33-8EA1-D57D7580D0D5Q37750239-7A3FD1B1-2411-4D0A-A9F1-FBF8F70F7976Q39449440-DABFF4E5-7529-40AD-9A44-5A6E785BF2FEQ40025713-836DD4CC-4189-4840-A0D1-6EDFAA175D90Q40263140-F07B96F8-B1CB-48E1-A442-05FE9C7E9D97Q40377576-E16C6705-700A-4082-9B50-27F38E552DB3Q40443282-5D97C7A6-EF6A-4CE1-830B-3A9241BBBA62Q40721588-ED8F457A-A026-483F-B25F-6465B24FEB5BQ41188002-7FE65B87-7085-4421-A8FF-7CD1BB8A9787Q41740537-083498A3-BAEA-468A-9DDF-4284B37C11D6Q41988533-840C8FD8-CBA7-4C0C-80E8-C4DD8759A913Q42465052-FB2E4235-2C43-4FB3-B9DB-0F14CEBEA3AFQ42486558-991BDD64-7882-4725-B3C3-08D9ADE66FACQ42508137-2594A298-6FE2-497B-856D-BE5208BF587DQ42545281-7595BFCA-B78F-4CA9-8E09-394613CFFF27Q42758136-3F2952B7-8F16-4C8C-A349-E2E446D43B32Q43291967-9374D159-F2E1-4C13-921C-DCA1ECD7728DQ44264439-9407DB4C-673D-4B71-9463-08880736ECDFQ44298045-25FE8E97-7BB5-47C6-A1E9-C6E854504BFDQ44842409-2C91221C-83F3-40F6-9637-706C7FDC7309Q44904985-4CDD49DE-F7EC-42FA-94CD-4FEC51BD4905Q45068395-92D41550-55C3-4E26-9733-B2C86FB7F4BB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
J. Timothy Greenamyre
@ast
J. Timothy Greenamyre
@en
J. Timothy Greenamyre
@es
J. Timothy Greenamyre
@nl
type
label
J. Timothy Greenamyre
@ast
J. Timothy Greenamyre
@en
J. Timothy Greenamyre
@es
J. Timothy Greenamyre
@nl
altLabel
J Timothy Greenamyre
@en
John T Greenamyre
@en
prefLabel
J. Timothy Greenamyre
@ast
J. Timothy Greenamyre
@en
J. Timothy Greenamyre
@es
J. Timothy Greenamyre
@nl
P108
P106
P108
P1153
57193303956
P31
P4012
P496
0000-0003-3468-7878